Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Niagen Bioscience, Inc. (NAGE)

2.3800 +0.0500 (+2.15%)
As of 12:31:18 PM EST. Market Open.
Trade NAGE on Coinbase
NAGE Q3 2026 earnings call
November 4, 2026 at 4:30 PM EST
Chart Range Bar
Loading chart for NAGE
  • Previous Close 2.3300
  • Open 2.3600
  • Bid 1.7000 x 200
  • Ask 3.0300 x 200
  • Day's Range 2.3500 - 2.4000
  • 52 Week Range 2.3200 - 7.9500
  • Volume 131,687
  • Avg. Volume 534,379
  • Market Cap (intraday) 189.554M
  • Beta (5Y Monthly) 2.08
  • PE Ratio (TTM) 12.53
  • EPS (TTM) 0.1900
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 11.92
  • Zacks Rating Bearish

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

www.niagenbioscience.com

117

Full Time Employees

December 31

Fiscal Year Ends

Packaged Foods

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NAGE
62.58%
S&P 500 (^GSPC)
11.15%

1-Year Return

NAGE
68.44%
S&P 500 (^GSPC)
11.23%

3-Year Return

NAGE
68.79%
S&P 500 (^GSPC)
76.22%

5-Year Return

NAGE
62.87%
S&P 500 (^GSPC)
64.31%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 29.79M
Earnings 963k
Profit Margin 3.23%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
10M
20M
30M
5.0%
10.0%
15.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

8.50
11.92 Average
2.3800 Current
22.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/31/2026
Analyst Canaccord Genuity
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 10 -> 9

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    184.76M

  • Enterprise Value

    120.35M

  • Trailing P/E

    12.29

  • Forward P/E

    16.68

  • PEG Ratio (current)

    0.52

  • Price/Sales (ttm)

    1.53

  • Price/Book (mrq)

    2.23

  • Enterprise Value/Revenue

    0.93

  • Enterprise Value/EBITDA

    7.15

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.39%

  • Return on Assets (ttm)

    5.44%

  • Return on Equity (ttm)

    21.80%

  • Revenue (ttm)

    129.08M

  • Net Income Avi to Common (ttm)

    15.99M

  • Diluted EPS (ttm)

    0.1900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    66.59M

  • Total Debt/Equity (mrq)

    2.82%

  • Levered Free Cash Flow (ttm)

    1.64M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

2.3800 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: